A new cohort joins the BaseLaunch accelerator

The selection committee of the BaseLaunch program has chosen 15 promising projects for Phase I. Together with BaseLaunch, Pharma partners, as well as a deep network of experts, will further assess each project and help to clearly articulate the near/mid-term milestones (preclinical, regulatory, commercial, and much more) required to further de-risk the science and build the companies. 

The selected projects include;

Alibion (Basel) – is a pre-clinical stage drug-development company developing the first personalized therapy against Rheumatoid arthritis.

PharmaBiome (Zurich) – pioneers bacterial mixes as microbiome therapeutics in IBD and oncology based on our mixed-culture technology.

SunRegen Healthcare (Basel-Land) – develops neuroprotective drugs for neurodegenerative diseases.

TOLREMO Therapeutics (Zurich) – is a cancer drug resistance company developing resistance-preventing small molecules to boost the long-term efficacy of existing cancer drugs to prolong patient survival.

INSIDER Therapeutics   (Zurich) – is a preclinical stage spin-off project from the University of Zurich. It is developing first-in-class small molecule anticancer therapeutics that modulate the epitranscriptomic code.

ImmProfile (Basel)  – is advancing innovative discoveries and solutions in immune-oncology.

Synoesis (New York) – is developing a first-in-class therapeutic to stop Parkinson’s disease.

ISARNA (Germany) - is a clinical-stage Biotech Company, addressing a high unmet medical need in Ophthalmology and beyond by developing innovative, targeted, first in class antisense blockbuster therapies for major blinding diseases.

GEBAMO (Denmark) – is bringing CRISPR-Cas12a technology forward.

Innervation Pharmaceuticals – is pre-clinical phase biotech. The company's patented, solid-phase transfection platform is used for genome-wide screening services and the discovery of genes that boost neuronal regrowth after spinal cord injury.

FoRx Therapeutics – is developing therapeutics that exploit the presence of DNA replication STRESS in human cancers.

CMET Pharmaceuticals – aims to develop novel therapies for the treatment of metastatic cancers, tailored to target circulating tumour cell clusters.

Biotech in stealth mode – is developing an antibody-based tumor therapy against a first-in-class target in the tumor microenvironment.

Biotech in stealth mode – is mode developing novel inhibitors of the inflammasome.

Biotech in stealth mode – a platform for finding new targets and developing novel drugs for solid cancers.

During the upcoming six months, the startups will develop their business ideas with the support of the BaseLaunch team and experienced entrepreneurs and consultants. In the first phase, each project will receive up to 10,000 Swiss francs. The selection committee will then select about three of Phase I projects to progress to Phase II. This phase lasts at least for 12 months, with each project receiving funding of up to 250,000 Swiss francs.

(Press release/RAN)